#

IPO

: 450
Anthropic Could Break SpaceXs Record for the Largest IPO in History / Photo: Samuel Boivin / Shutterstock.com
News·
Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16
Anthropics valuation rose 25% to $1.5 trillion / Photo: PJ McDonnell / Shutterstock.com
News·
Anthropic's valuation jumped 25% in a month to reach $1.5 trillion — Business Insider
ERock, a manufacturer of power units for data centers, went public in June 2026 / Photo: X/NYSE
News·
BofA has raised its forecast for ERock twice this month. It is seen as a bet on Anthropic's IPO.
Anthropics IPO Could Set a Record / Photo: Anthropic
News·
Anthropic's investors are banking on a $2 trillion valuation and a record-breaking IPO — FT
Anthropic is in talks to acquire the AI startup Decart AI for $6 billion / Photo: Ascannio / Shutterstock.com
Review·
Top Stories This Morning: Anthropic Is Preparing Its Largest Acquisition; Cerebras Plummets After Earnings Report
Shein expects to be valued at $30–40 billion following its IPO, according to Reuters / Photo: X/SHEIN_Oficial
News·
Shein, the $5 T-shirt retailer, is preparing to go public in Hong Kong on August 19 — Reuters
OpenAIs valuation has remained unchanged over the past five months, according to the results of a share buyback / Photo: doomu / Shutterstock.com
News·
OpenAI bought back $7 billion worth of shares from employees at the old price. The price has not risen since March.
Robot manufacturer Unitree Robotics is preparing to begin accepting applications from investors to participate in its IPO on the STAR Market in Shanghai / Photo: helloabc / Shutterstock.com
News·
Robots Backed by DeepSeek Investments and a Wave of Biotech IPOs: Key Takeaways on IPOs Through August 9
Latigo was created by venture capital firm Westlake BioPartners and staffed with former neuroscience employees from Amgen / Photo: THICHA SATAPITANON / Shutterstock
Small Caps·
+1
·
Latigo IPO: Non-opioid painkiller maker debuts on the Nasdaq
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
News·
BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
Photo: Seacalm/Shutterstock
News·
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available
Attovia is developing drugs using a licensed technology platform and patents, with one drug having completed dosing in a phase I trial and another expected to start trials in early 2027 / Photo: Unsplash / Mathurin Napoli / matnapo
Small Caps·
+1
·
Attovia IPO: Goldman-backed biotech debuts on the Nasdaq
Load more